Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for ML-007C-MA (Undisclosed Mechanism) in Schizophrenia. The expected timing is based on the latest available company guidance and may change.
05/14/26:- ZEPHYR enrolled 307 participants. Topline Phase 2 results remain expected by Mid-August 2026. 07/27/26:- ZEPHYR Ph2 topline positive. Company plans EOP2 FDA meeting and additional registrational confirmatory trial. 08/13/26:- ZEPHYR Phase 2 results were positive. An End-of-Phase 2 Food and Drug Administration meeting is planned. ZEPHYR-2 Phase 3 topline results are expected in 2028.
Verification
Confirm timing and program details against the company announcement or filing.